Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Roche upgraded to Add from Reduce at AlphaValue » 12:55
07/03/20
07/03
12:55
07/03/20
12:55
RHHBY

Roche

$0.00 /

+ (+0.00%)

AlphaValue upgraded Roche…

AlphaValue upgraded Roche to Add from Reduce.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Over a week ago
Recommendations
Herceptin/Perjecta approval another win for Halozyme, says Piper » 14:57
06/29/20
06/29
14:57
06/29/20
14:57
HALO

Halozyme

$25.70 /

+0.91 (+3.67%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $28 price target on Halozyme Therapeutics (HALO) after Halozyme partner Roche (RHHBY) received approval for the subQ FDC of Herceptin/Perjeta using Halozyme's ENHANZE technology. Catanzaro noted that the approval comes "well ahead" of the October 18 PDUFA data and comes with a broad label that covers both early-stage and metastatic disease. Catanzaro said that, overall, he thinks that Phesgo could be an underappreciated blockbuster product which he expects will drive another inflection in royalties for Halozyme on top of the recently approved Darzalex Faspro.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

HALO Halozyme
$25.70 /

+0.91 (+3.67%)

HALO Halozyme
$25.70 /

+0.91 (+3.67%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
RHHBY Roche
$0.00 /

+ (+0.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
RHHBY Roche
$0.00 /

+ (+0.00%)

HALO Halozyme
$25.70 /

+0.91 (+3.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

HALO Halozyme
$25.70 /

+0.91 (+3.67%)

Hot Stocks
Halozyme announces FDA approval of Roche's Phesgo with Enhanze technology » 12:59
06/29/20
06/29
12:59
06/29/20
12:59
HALO

Halozyme

$25.60 /

+0.81 (+3.27%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Halozyme Therapeutics…

Halozyme Therapeutics (HALO) announced that the U.S. FDA has approved Roche's (RHHBY) Phesgo injection, a fixed-dose combination of Perjeta and Herceptin with Halozyme's ENHANZE technology, administered subcutaneously in combination with intravenous chemotherapy, for the treatment of eligible patients with early and metastatic HER2-positive breast cancer. This is the first time a product has been approved combining two monoclonal antibodies that can be administered by a single subcutaneous injection utilizing Halozyme's ENHANZE technology. "We are excited that HER2-positive breast cancer patients in the U.S. will now have the option to receive this important therapy in a meaningfully shorter period of time," said Dr. Helen Torley, president and CEO. "This subcutaneous delivery was shown to be preferred to IV administration by 85% of patients in the PHranceSCa study due to less time in the clinic and more comfortable treatment administration. Phesgo is the second product to receive FDA approval this year, and the first demonstrating the ability to combine two monoclonal antibodies, utilizing our ENHANZE technology."

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

HALO Halozyme
$25.60 /

+0.81 (+3.27%)

HALO Halozyme
$25.60 /

+0.81 (+3.27%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
RHHBY Roche
$0.00 /

+ (+0.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
RHHBY Roche
$0.00 /

+ (+0.00%)

HALO Halozyme
$25.60 /

+0.81 (+3.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

HALO Halozyme
$25.60 /

+0.81 (+3.27%)

Hot Stocks
FDA approves Genentech's Phesgo for HER2-positive breast cancer » 12:54
06/29/20
06/29
12:54
06/29/20
12:54
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Phesgo, a fixed-dose combination of Perjeta and Herceptin with hyaluronidase, administered by subcutaneous injection in combination with intravenous chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Genentech has combined two monoclonal antibodies that can be administered by a single SC injection. "The FDA approval of Phesgo reflects our commitment to improving outcomes for the many people living with HER2-positive breast cancer," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Phesgo offers a treatment administration that supports the needs and preferences of individual patients, and helps to meet the increasing demand across the healthcare system for faster and more flexible treatment options." The approval is based on results from the pivotal Phase III FeDeriCa study, which met its primary endpoint with Phesgo showing non-inferior levels of Perjeta in the blood during a given dosing interval when compared to IV administration of Perjeta. The safety profile of Phesgo with chemotherapy was comparable to IV administration of Perjeta plus Herceptin and chemotherapy, and no new safety signals were identified, including no meaningful difference in cardiac toxicity.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Periodicals
Roche says COVID tests demand exceeds production, Bloomberg reports » 16:35
06/28/20
06/28
16:35
06/28/20
16:35
RHHBY

Roche

$0.00 /

+ (+0.00%)

Roche's production…

Roche's production of coronavirus tests is falling behind in meeting the outsize global demand for them, Bloomberg's Marion Halftermeyer reports. "The PCR tests that detect acute COVID infection, the demand exceeds our production," Roche Chairman Christoph Franz said in an interview with Swiss daily newspaper Tages Anzeiger. The pharmaceutical giant said it prioritizes sending tests based on medical needs and where the highest infection rates are, according to the paper. Reference Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

On The Fly
Fly Intel: Wall Street's top stories for Thursday » 16:37
06/25/20
06/25
16:37
06/25/20
16:37
BAC

Bank of America

$24.72 /

+0.89 (+3.73%)

, WFC

Wells Fargo

$27.36 /

+1.22 (+4.67%)

, JPM

JPMorgan

$97.88 /

+3.21 (+3.39%)

, MS

Morgan Stanley

$48.79 /

+1.84 (+3.92%)

, C

Citi

$52.71 /

+1.88 (+3.70%)

, GS

Goldman Sachs

$207.37 /

+9.4 (+4.75%)

, DIS

Disney

$111.38 /

-0.69 (-0.62%)

, M

Macy's

$6.50 /

-0.28 (-4.13%)

, BA

Boeing

$174.91 /

-1.75 (-0.99%)

, AAPL

Apple

$364.85 /

+4.8 (+1.33%)

, ATHX

Athersys

$2.88 /

+0.665 (+30.09%)

, ACN

Accenture

$217.43 /

+15.575 (+7.72%)

, QURE

uniQure

$49.21 /

-13.64 (-21.70%)

, KBH

KB Home

$29.44 /

-3.94 (-11.80%)

Stocks began the session…

Open Full Text

ShowHide Related Items >><<
WFC Wells Fargo
$27.36 /

+1.22 (+4.67%)

QURE uniQure
$49.21 /

-13.64 (-21.70%)

MS Morgan Stanley
$48.79 /

+1.84 (+3.92%)

M Macy's
$6.50 /

-0.28 (-4.13%)

KBH KB Home
$29.44 /

-3.94 (-11.80%)

JPM JPMorgan
$97.88 /

+3.21 (+3.39%)

GS Goldman Sachs
$207.37 /

+9.4 (+4.75%)

DIS Disney
$111.38 /

-0.69 (-0.62%)

C Citi
$52.71 /

+1.88 (+3.70%)

BAC Bank of America
$24.72 /

+0.89 (+3.73%)

BA Boeing
$174.91 /

-1.75 (-0.99%)

ATHX Athersys
$2.88 /

+0.665 (+30.09%)

ACN Accenture
$217.43 /

+15.575 (+7.72%)

AAPL Apple
$364.85 /

+4.8 (+1.33%)

BAC Bank of America
$24.72 /

+0.89 (+3.73%)

06/23/20 Wells Fargo
Finicity should help MasterCard with open banking efforts, says Wells Fargo
06/11/20 BTIG
First Department ruling 'a significant positive' for Ambac Financial, says BTIG
06/05/20 Wells Fargo
Bank of America price target raised to $35 from $30 at Wells Fargo
04/16/20 DA Davidson
Bank of America price target raised to $26 from $24 at DA Davidson
WFC Wells Fargo
$27.36 /

+1.22 (+4.67%)

06/26/20 Morgan Stanley
Morgan Stanley sees dividend cuts at Wells Fargo, Capital One after stress tests
06/11/20 JPMorgan
Wells Fargo dividend very likely to be cut, says JPMorgan
06/11/20 Morgan Stanley
Morgan Stanley trims Wells Fargo price target to $27, forecasts dividend cut
06/04/20
Fly Intel: Top five analyst upgrades
JPM JPMorgan
$97.88 /

+3.21 (+3.39%)

06/05/20 Wells Fargo
JPMorgan price target raised to $130 from $115 at Wells Fargo
05/20/20 Odeon Capital
JPMorgan upgraded to Buy from Hold at Odeon Capital
MS Morgan Stanley
$48.79 /

+1.84 (+3.92%)

06/24/20
Fly Intel: Top five analyst upgrades
06/24/20 DA Davidson
Morgan Stanley upgraded to Buy from Neutral at DA Davidson
06/24/20 DA Davidson
Morgan Stanley upgraded to Buy from Neutral at DA Davidson
06/05/20 Wells Fargo
Morgan Stanley price target raised to $51 from $40 at Wells Fargo
C Citi
$52.71 /

+1.88 (+3.70%)

06/09/20 Standpoint Research
Citi downgraded to Hold from Buy at Standpoint Research
06/05/20 Wells Fargo
Citi price target raised to $72 from $60 at Wells Fargo
06/02/20 Odeon Capital
Citi upgraded to Buy from Hold at Odeon Capital
GS Goldman Sachs
$207.37 /

+9.4 (+4.75%)

06/05/20 Wells Fargo
Goldman Sachs price target raised to $255 from $230 at Wells Fargo
06/04/20
Fly Intel: Top five analyst downgrades
06/03/20 Deutsche Bank
Wells Fargo upgraded to Buy, Goldman Sachs cut to Hold at Deutsche Bank
DIS Disney
$111.38 /

-0.69 (-0.62%)

06/24/20 Morgan Stanley
Morgan Stanley says time might be right for Disney to move ESPN to streaming
06/19/20 Wells Fargo
Disney price target raised to $118 from $107 at Wells Fargo
06/15/20 BofA
BofA boosts Disney target to $146, sees 'compelling' entry point
06/09/20
Fly Intel: Top five analyst downgrades
M Macy's
$6.50 /

-0.28 (-4.13%)

06/16/20 Loop Capital
Loop keeps Hold on Ulta Beauty on concerns promotions could be 'contagious'
06/10/20 Morgan Stanley
Macy's 'setting the bar low' for second quarter, says Morgan Stanley
05/22/20 Deutsche Bank
Macy's price target lowered to $5 from $7 at Deutsche Bank
05/07/20 Deutsche Bank
Macy's price target lowered to $7 from $20 at Deutsche Bank
BA Boeing
$174.91 /

-1.75 (-0.99%)

06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
06/26/20 Bernstein
Boeing downgraded to Market Perform from Outperform at Bernstein
06/25/20
Fly Intel: Top five analyst downgrades
06/25/20 Berenberg
Berenberg says Boeing pricing in too much optimism, downgrades to Sell
AAPL Apple
$364.85 /

+4.8 (+1.33%)

06/26/20 Evercore ISI
Evercore upgrades Broadcom to Outperform, sees Apple sales driving upside
06/25/20 Wedbush
Wedbush boosts Apple target to $425, sees $2 trillion valuation in 2021
06/24/20 BMO Capital
Criteo downgraded to Market Perform from Outperform at BMO Capital
06/23/20 Baird
Apple price target raised to $390 from $320 at Baird
ATHX Athersys
$2.88 /

+0.665 (+30.09%)

06/25/20 BofA
Athersys initiated with a Buy at BofA
06/25/20 BofA
Athersys initiated with a Buy at BofA
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
04/23/20 SMBC Nikko
Athersys initiated with an Outperform at SMBC Nikko
ACN Accenture
$217.43 /

+15.575 (+7.72%)

06/26/20 Deutsche Bank
Accenture price target raised to $245 from $215 at Deutsche Bank
06/26/20 Citi
Accenture price target raised to $247 from $230 at Citi
06/23/20 Morgan Stanley
Accenture price target raised to $230 from $185 at Morgan Stanley
06/22/20 Piper Sandler
Piper Sandler cautious on Accenture into earnings
QURE uniQure
$49.21 /

-13.64 (-21.70%)

06/25/20 Guggenheim
uniQure HemB deal 'not the M&A some investors were hoping for,' says Guggenheim
06/25/20 H.C. Wainwright
uniQure price target lowered to $64 from $73 at H.C. Wainwright
06/25/20 Stifel
uniQure price target lowered to $78 from $86 at Stifel
KBH KB Home
$29.44 /

-3.94 (-11.80%)

06/25/20 Wells Fargo
KB Home price target raised to $33 from $24 at Wells Fargo
06/25/20 RBC Capital
KB Home price target lowered to $33 from $34 at RBC Capital
06/25/20 Evercore ISI
KB Home downgraded to In Line from Outperform at Evercore ISI
WFC Wells Fargo
$27.36 /

+1.22 (+4.67%)

QURE uniQure
$49.21 /

-13.64 (-21.70%)

MS Morgan Stanley
$48.79 /

+1.84 (+3.92%)

M Macy's
$6.50 /

-0.28 (-4.13%)

KBH KB Home
$29.44 /

-3.94 (-11.80%)

JPM JPMorgan
$97.88 /

+3.21 (+3.39%)

GS Goldman Sachs
$207.37 /

+9.4 (+4.75%)

DIS Disney
$111.38 /

-0.69 (-0.62%)

C Citi
$52.71 /

+1.88 (+3.70%)

BAC Bank of America
$24.72 /

+0.89 (+3.73%)

BA Boeing
$174.91 /

-1.75 (-0.99%)

ACN Accenture
$217.43 /

+15.575 (+7.72%)

AAPL Apple
$364.85 /

+4.8 (+1.33%)

  • 16
    Apr
  • 06
    Sep
WFC Wells Fargo
$27.36 /

+1.22 (+4.67%)

MS Morgan Stanley
$48.79 /

+1.84 (+3.92%)

M Macy's
$6.50 /

-0.28 (-4.13%)

JPM JPMorgan
$97.88 /

+3.21 (+3.39%)

GS Goldman Sachs
$207.37 /

+9.4 (+4.75%)

DIS Disney
$111.38 /

-0.69 (-0.62%)

C Citi
$52.71 /

+1.88 (+3.70%)

BAC Bank of America
$24.72 /

+0.89 (+3.73%)

BA Boeing
$174.91 /

-1.75 (-0.99%)

ATHX Athersys
$2.88 /

+0.665 (+30.09%)

ACN Accenture
$217.43 /

+15.575 (+7.72%)

AAPL Apple
$364.85 /

+4.8 (+1.33%)

WFC Wells Fargo
$27.36 /

+1.22 (+4.67%)

QURE uniQure
$49.21 /

-13.64 (-21.70%)

MS Morgan Stanley
$48.79 /

+1.84 (+3.92%)

M Macy's
$6.50 /

-0.28 (-4.13%)

KBH KB Home
$29.44 /

-3.94 (-11.80%)

JPM JPMorgan
$97.88 /

+3.21 (+3.39%)

DIS Disney
$111.38 /

-0.69 (-0.62%)

C Citi
$52.71 /

+1.88 (+3.70%)

BAC Bank of America
$24.72 /

+0.89 (+3.73%)

BA Boeing
$174.91 /

-1.75 (-0.99%)

ATHX Athersys
$2.88 /

+0.665 (+30.09%)

ACN Accenture
$217.43 /

+15.575 (+7.72%)

AAPL Apple
$364.85 /

+4.8 (+1.33%)

WFC Wells Fargo
$27.36 /

+1.22 (+4.67%)

QURE uniQure
$49.21 /

-13.64 (-21.70%)

MS Morgan Stanley
$48.79 /

+1.84 (+3.92%)

M Macy's
$6.50 /

-0.28 (-4.13%)

KBH KB Home
$29.44 /

-3.94 (-11.80%)

JPM JPMorgan
$97.88 /

+3.21 (+3.39%)

GS Goldman Sachs
$207.37 /

+9.4 (+4.75%)

DIS Disney
$111.38 /

-0.69 (-0.62%)

C Citi
$52.71 /

+1.88 (+3.70%)

BAC Bank of America
$24.72 /

+0.89 (+3.73%)

BA Boeing
$174.91 /

-1.75 (-0.99%)

ACN Accenture
$217.43 /

+15.575 (+7.72%)

AAPL Apple
$364.85 /

+4.8 (+1.33%)

C Citi
$52.71 /

+1.88 (+3.70%)

AAPL Apple
$364.85 /

+4.8 (+1.33%)

On The Fly
uniQure plunges as takeover hopes dented by licensing deal » 14:26
06/25/20
06/25
14:26
06/25/20
14:26
QURE

uniQure

$49.46 /

-13.39 (-21.30%)

Shares of uniQure (QURE)…

Open Full Text

ShowHide Related Items >><<
QURE uniQure
$49.46 /

-13.39 (-21.30%)

QURE uniQure
$49.46 /

-13.39 (-21.30%)

06/25/20
Fly Intel: Top five analyst downgrades
06/25/20 Guggenheim
uniQure HemB deal 'not the M&A some investors were hoping for,' says Guggenheim
06/25/20 H.C. Wainwright
uniQure price target lowered to $64 from $73 at H.C. Wainwright
06/25/20 Stifel
uniQure price target lowered to $78 from $86 at Stifel
QURE uniQure
$49.46 /

-13.39 (-21.30%)

  • 06
    Sep
QURE uniQure
$49.46 /

-13.39 (-21.30%)

QURE uniQure
$49.46 /

-13.39 (-21.30%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:03
06/25/20
06/25
12:03
06/25/20
12:03
DIS

Disney

$109.88 /

-2.19 (-1.95%)

, M

Macy's

$6.47 /

-0.31 (-4.57%)

, BA

Boeing

$173.03 /

-3.63 (-2.05%)

, ATHX

Athersys

$2.81 /

+0.6 (+27.15%)

, RAD

Rite Aid

$15.60 /

+2.74 (+21.31%)

, QURE

uniQure

$50.08 /

-12.77 (-20.32%)

, KBH

KB Home

$29.51 /

-3.87 (-11.59%)

Stocks began the session…

Open Full Text

ShowHide Related Items >><<
RAD Rite Aid
$15.60 /

+2.74 (+21.31%)

QURE uniQure
$50.08 /

-12.77 (-20.32%)

M Macy's
$6.47 /

-0.31 (-4.57%)

KBH KB Home
$29.51 /

-3.87 (-11.59%)

DIS Disney
$109.88 /

-2.19 (-1.95%)

BA Boeing
$173.03 /

-3.63 (-2.05%)

ATHX Athersys
$2.81 /

+0.6 (+27.15%)

DIS Disney
$109.88 /

-2.19 (-1.95%)

06/24/20 Morgan Stanley
Morgan Stanley says time might be right for Disney to move ESPN to streaming
06/19/20 Wells Fargo
Disney price target raised to $118 from $107 at Wells Fargo
06/15/20 BofA
BofA boosts Disney target to $146, sees 'compelling' entry point
06/09/20
Fly Intel: Top five analyst downgrades
M Macy's
$6.47 /

-0.31 (-4.57%)

06/16/20 Loop Capital
Loop keeps Hold on Ulta Beauty on concerns promotions could be 'contagious'
06/10/20 Morgan Stanley
Macy's 'setting the bar low' for second quarter, says Morgan Stanley
05/22/20 Deutsche Bank
Macy's price target lowered to $5 from $7 at Deutsche Bank
05/07/20 Deutsche Bank
Macy's price target lowered to $7 from $20 at Deutsche Bank
BA Boeing
$173.03 /

-3.63 (-2.05%)

06/25/20
Fly Intel: Top five analyst downgrades
06/25/20 Berenberg
Berenberg says Boeing pricing in too much optimism, downgrades to Sell
06/25/20 Berenberg
Boeing downgraded to Sell from Hold at Berenberg
06/24/20 Jefferies
Boeing's 777x likely to replace 40% of legacy demand, says Jefferies
ATHX Athersys
$2.81 /

+0.6 (+27.15%)

06/25/20 BofA
Athersys initiated with a Buy at BofA
06/25/20 BofA
Athersys initiated with a Buy at BofA
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
04/23/20 SMBC Nikko
Athersys initiated with an Outperform at SMBC Nikko
RAD Rite Aid
$15.60 /

+2.74 (+21.31%)

04/17/20
Fly Intel: Top five analyst upgrades
04/17/20 Deutsche Bank
Rite Aid upgraded to Hold from Sell at Deutsche Bank
02/27/20
Fly Intel: Top five analyst upgrades
02/27/20 Guggenheim
Rite Aid upgraded to Neutral ahead of analyst day at Guggenheim
QURE uniQure
$50.08 /

-12.77 (-20.32%)

06/25/20 Guggenheim
uniQure HemB deal 'not the M&A some investors were hoping for,' says Guggenheim
06/25/20 H.C. Wainwright
uniQure price target lowered to $64 from $73 at H.C. Wainwright
06/25/20 Stifel
uniQure price target lowered to $78 from $86 at Stifel
KBH KB Home
$29.51 /

-3.87 (-11.59%)

06/25/20 Wells Fargo
KB Home price target raised to $33 from $24 at Wells Fargo
06/25/20 RBC Capital
KB Home price target lowered to $33 from $34 at RBC Capital
06/25/20 Evercore ISI
KB Home downgraded to In Line from Outperform at Evercore ISI
RAD Rite Aid
$15.60 /

+2.74 (+21.31%)

QURE uniQure
$50.08 /

-12.77 (-20.32%)

M Macy's
$6.47 /

-0.31 (-4.57%)

KBH KB Home
$29.51 /

-3.87 (-11.59%)

DIS Disney
$109.88 /

-2.19 (-1.95%)

BA Boeing
$173.03 /

-3.63 (-2.05%)

M Macy's
$6.47 /

-0.31 (-4.57%)

DIS Disney
$109.88 /

-2.19 (-1.95%)

BA Boeing
$173.03 /

-3.63 (-2.05%)

ATHX Athersys
$2.81 /

+0.6 (+27.15%)

RAD Rite Aid
$15.60 /

+2.74 (+21.31%)

QURE uniQure
$50.08 /

-12.77 (-20.32%)

M Macy's
$6.47 /

-0.31 (-4.57%)

KBH KB Home
$29.51 /

-3.87 (-11.59%)

DIS Disney
$109.88 /

-2.19 (-1.95%)

BA Boeing
$173.03 /

-3.63 (-2.05%)

ATHX Athersys
$2.81 /

+0.6 (+27.15%)

RAD Rite Aid
$15.60 /

+2.74 (+21.31%)

QURE uniQure
$50.08 /

-12.77 (-20.32%)

M Macy's
$6.47 /

-0.31 (-4.57%)

KBH KB Home
$29.51 /

-3.87 (-11.59%)

DIS Disney
$109.88 /

-2.19 (-1.95%)

BA Boeing
$173.03 /

-3.63 (-2.05%)

On The Fly
Peloton resumption, DocuSign initiation among today's top calls on Wall Street » 10:02
06/25/20
06/25
10:02
06/25/20
10:02
PTON

Peloton

$55.42 /

-0.07 (-0.13%)

, DOCU

DocuSign

$163.09 /

-0.8 (-0.49%)

, SEDG

SolarEdge

$141.97 /

-6.29 (-4.24%)

, VSLR

Vivint Solar

$9.40 /

-0.64 (-6.37%)

, ALL

Allstate

$93.45 /

+0.56 (+0.60%)

, QURE

uniQure

$52.32 /

-10.53 (-16.75%)

Check out today's top…

Open Full Text

ShowHide Related Items >><<
VSLR Vivint Solar
$9.40 /

-0.64 (-6.37%)

SEDG SolarEdge
$141.97 /

-6.29 (-4.24%)

QURE uniQure
$52.32 /

-10.53 (-16.75%)

PTON Peloton
$55.42 /

-0.07 (-0.13%)

DOCU DocuSign
$163.09 /

-0.8 (-0.49%)

ALL Allstate
$93.45 /

+0.56 (+0.60%)

PTON Peloton
$55.42 /

-0.07 (-0.13%)

06/25/20 Raymond James
Peloton resumed with an Outperform at Raymond James
06/24/20 KeyBanc
Peloton price target raised to $70 from $55 at KeyBanc
06/23/20 Cowen
Peloton price target raised to $70 from $54 at Cowen
06/22/20 Stifel
Stifel boosts Peloton target to $62, sees 'holiday-like' demand continuing
DOCU DocuSign
$163.09 /

-0.8 (-0.49%)

06/24/20 Oppenheimer
DocuSign initiated with an Outperform at Oppenheimer
06/24/20 Oppenheimer
DocuSign initiated with an Outperform at Oppenheimer
06/24/20 Goldman Sachs
DocuSign price target raised to $175 from $100 at Goldman Sachs
06/23/20
Fly Intel: Top five analyst initiations
SEDG SolarEdge
$141.97 /

-6.29 (-4.24%)

06/24/20 Goldman Sachs
SolarEdge downgraded to Sell from Neutral at Goldman Sachs
06/15/20 GLJ Research
Solar space earnings likely cut through remainder of 2020, says GLJ Research
06/04/20 GLJ Research
GLJ Research sees potential for SolarEdge margins to fall further through 2020
05/28/20 JPMorgan
SolarEdge price target raised to $166 from $131 at JPMorgan
VSLR Vivint Solar
$9.40 /

-0.64 (-6.37%)

06/24/20 Goldman Sachs
Vivint Solar downgraded to Neutral from Buy at Goldman Sachs
06/05/20 JMP Securities
Vivint Solar price target raised to $15 from $10 at JMP Securities
06/02/20 Roth Capital
Roth says loan securitizations reopening a positive for residential solar names
03/25/20 Roth Capital
ITC extension 'NOT' in Phase 3 coronavirus rescue package, says Roth Capital
ALL Allstate
$93.45 /

+0.56 (+0.60%)

06/25/20
Fly Intel: Top five analyst upgrades
06/25/20 Credit Suisse
Allstate upgraded to Neutral from Underperform at Credit Suisse
06/01/20 BofA
Allstate reinstated with a Buy at BofA
05/06/20 JPMorgan
Allstate results affirm bullish view, says JPMorgan
QURE uniQure
$52.32 /

-10.53 (-16.75%)

06/25/20
Fly Intel: Top five analyst downgrades
06/25/20 Guggenheim
uniQure HemB deal 'not the M&A some investors were hoping for,' says Guggenheim
06/25/20 H.C. Wainwright
uniQure price target lowered to $64 from $73 at H.C. Wainwright
06/25/20 Stifel
uniQure price target lowered to $78 from $86 at Stifel
VSLR Vivint Solar
$9.40 /

-0.64 (-6.37%)

SEDG SolarEdge
$141.97 /

-6.29 (-4.24%)

QURE uniQure
$52.32 /

-10.53 (-16.75%)

PTON Peloton
$55.42 /

-0.07 (-0.13%)

DOCU DocuSign
$163.09 /

-0.8 (-0.49%)

ALL Allstate
$93.45 /

+0.56 (+0.60%)

VSLR Vivint Solar
$9.40 /

-0.64 (-6.37%)

PTON Peloton
$55.42 /

-0.07 (-0.13%)

VSLR Vivint Solar
$9.40 /

-0.64 (-6.37%)

SEDG SolarEdge
$141.97 /

-6.29 (-4.24%)

QURE uniQure
$52.32 /

-10.53 (-16.75%)

PTON Peloton
$55.42 /

-0.07 (-0.13%)

DOCU DocuSign
$163.09 /

-0.8 (-0.49%)

VSLR Vivint Solar
$9.40 /

-0.64 (-6.37%)

SEDG SolarEdge
$141.97 /

-6.29 (-4.24%)

QURE uniQure
$52.32 /

-10.53 (-16.75%)

PTON Peloton
$55.42 /

-0.07 (-0.13%)

DOCU DocuSign
$163.09 /

-0.8 (-0.49%)

Downgrade
Fly Intel: Top five analyst downgrades » 09:59
06/25/20
06/25
09:59
06/25/20
09:59
BA

Boeing

$170.81 /

-5.85 (-3.31%)

, HPP

Hudson Pacific

$23.31 /

-0.61 (-2.55%)

, TTM

Tata Motors

$6.55 /

-0.16 (-2.38%)

, QURE

uniQure

$52.07 /

-10.785 (-17.16%)

, KBH

KB Home

$28.90 /

-4.48 (-13.42%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boeing (BA) downgraded to Sell from Hold at Berenberg with analyst Andrew Gollan suggesting investors "lock in any gains" ahead of what should be weak Q2 results next month. 2. Hudson Pacific (HPP) cut to Equal Weight from Overweight at Morgan Stanley with analyst Vikram Malhotra saying the impact of work-from-home trend is weighing on office REIT fundamentals. 3. uniQure (QURE) was downgraded to Neutral from Outperform at Baird and to Equal Weight from Overweight at Wells Fargo. 4. Tata Motors (TTM) downgraded to Sell from Neutral at Goldman Sachs with analyst Pramod Kumar saying the company's attempts to "revive" Jaguar Land Rover and the India car business have not yielded results amid a worsening industry environment. 5. KB Home (KBH) downgraded to In Line from Outperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
QURE uniQure
$52.07 /

-10.785 (-17.16%)

KBH KB Home
$28.90 /

-4.48 (-13.42%)

HPP Hudson Pacific
$23.31 /

-0.61 (-2.55%)

BA Boeing
$170.81 /

-5.85 (-3.31%)

BA Boeing
$170.81 /

-5.85 (-3.31%)

06/25/20 Berenberg
Berenberg says Boeing pricing in too much optimism, downgrades to Sell
06/25/20 Berenberg
Boeing downgraded to Sell from Hold at Berenberg
06/24/20 Jefferies
Boeing's 777x likely to replace 40% of legacy demand, says Jefferies
06/11/20 Susquehanna
Boeing price target raised to $240 from $175 at Susquehanna
HPP Hudson Pacific
$23.31 /

-0.61 (-2.55%)

06/24/20 Morgan Stanley
Hudson Pacific cut to Equal Weight from Overweight at Morgan Stanley
04/16/20 Jefferies
Hudson Pacific initiated with a Hold at Jefferies
02/04/20 Mizuho
Hudson Pacific assumed with a Buy at Mizuho
01/15/20 Mizuho
Hudson Pacific upgraded to Buy from Neutral at Mizuho
TTM Tata Motors
$6.55 /

-0.16 (-2.38%)

06/25/20 Goldman Sachs
Tata Motors downgraded to Sell from Neutral at Goldman Sachs
06/16/20
Fly Intel: Top five analyst downgrades
06/16/20 JPMorgan
Tata Motors downgraded to Underweight from Neutral at JPMorgan
05/11/20 CLSA
Tata Motors downgraded to Underperform from Buy at CLSA
QURE uniQure
$52.07 /

-10.785 (-17.16%)

06/25/20 Guggenheim
uniQure HemB deal 'not the M&A some investors were hoping for,' says Guggenheim
06/25/20 H.C. Wainwright
uniQure price target lowered to $64 from $73 at H.C. Wainwright
06/25/20 Stifel
uniQure price target lowered to $78 from $86 at Stifel
06/25/20 Mizuho
uniQure downgraded to Neutral from Buy at Mizuho
KBH KB Home
$28.90 /

-4.48 (-13.42%)

06/25/20 Wells Fargo
KB Home price target raised to $33 from $24 at Wells Fargo
06/25/20 RBC Capital
KB Home price target lowered to $33 from $34 at RBC Capital
06/25/20 Evercore ISI
KB Home downgraded to In Line from Outperform at Evercore ISI
06/11/20 JPMorgan
PulteGroup upgraded, KB downgraded as JPMorgan adjusts homebuilder ratings
QURE uniQure
$52.07 /

-10.785 (-17.16%)

KBH KB Home
$28.90 /

-4.48 (-13.42%)

HPP Hudson Pacific
$23.31 /

-0.61 (-2.55%)

BA Boeing
$170.81 /

-5.85 (-3.31%)

TTM Tata Motors
$6.55 /

-0.16 (-2.38%)

HPP Hudson Pacific
$23.31 /

-0.61 (-2.55%)

BA Boeing
$170.81 /

-5.85 (-3.31%)

TTM Tata Motors
$6.55 /

-0.16 (-2.38%)

QURE uniQure
$52.07 /

-10.785 (-17.16%)

KBH KB Home
$28.90 /

-4.48 (-13.42%)

HPP Hudson Pacific
$23.31 /

-0.61 (-2.55%)

BA Boeing
$170.81 /

-5.85 (-3.31%)

QURE uniQure
$52.07 /

-10.785 (-17.16%)

KBH KB Home
$28.90 /

-4.48 (-13.42%)

BA Boeing
$170.81 /

-5.85 (-3.31%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.